{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:02:13Z","timestamp":1791928933601,"version":"4.3.4"},"reference-count":17,"publisher":"S. Karger AG","issue":"3-4","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Neurol"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; The prospective, non-interventional Mobility Improvement (MOVE) 2 study was designed to provide real life data on clinical outcomes of patients with treatment-resistant multiple sclerosis (MS) spasticity receiving routine treatment with tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (Sativex\u00ae), subsequent to its approval in European countries. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; This interim analysis reports on MOVE 2 patients from Italy. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Interim data from 322 patients (58.3% female; mean age 51.1 \u00b1 10.2 years) were analyzed. From baseline to month 3 of treatment (Visit 3), the mean 0-10 Numerical Rating Scale (NRS) score decreased by -19.1% (-1.6 points, p &lt; 0.0001) and the mean modified Ashworth score decreased from 2.6 to 2.3 points (p &lt; 0.0001). At Visit 3, 24.6% of 203 patients with available data were clinically relevant responders (\u226530% improvement from baseline NRS score; p &lt; 0.001 vs. baseline). The mean reported dose of THC:CBD oromucosal spray was 6.1 \u00b1 2.5 sprays\/day at Visit 1 (1 month) and 5.1 \u00b1 2.6 sprays\/day at Visit 3 (range 1-12 sprays\/day at both timepoints). Forty-one (13.1%) patients reported at least one adverse event (AE), which included 3 serious AEs (1 unrelated). AEs with an incidence \u22651% were dizziness (5.6%), confusion (2.5%), nausea (1.25%) and somnolence (1.25%). &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; In everyday clinical practice in Italy, THC:CBD oromucosal spray provided symptomatic relief of MS spasticity with good tolerability in a relevant number of previously resistant patients.<\/jats:p>","DOI":"10.1159\/000441619","type":"journal-article","created":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T22:01:17Z","timestamp":1447711277000},"page":"178-185","source":"Crossref","is-referenced-by-count":16,"title":["Effectiveness and Tolerability of THC\/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study"],"prefix":"10.1159","volume":"74","author":[{"given":"Maria","family":"Trojano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2015,11,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01342.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-128"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70064-8"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048078"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2012-053"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2012.762364"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2011-000155"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-3787(12)70046-2"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmr.2013.07.003"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12202"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2217\/nmt.14.44"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1191\/1352458504ms1082oa"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01639.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1179\/016164109X12590518685660"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03328.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000357427"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.05.011"}],"container-title":["European Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/441619","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/441619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:02:36Z","timestamp":1745431356000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000441619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":17,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000441619","archive":["Portico"],"relation":{},"ISSN":["0014-3022","1421-9913"],"issn-type":[{"value":"0014-3022","type":"print"},{"value":"1421-9913","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}